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Remarkable advances have recently developed in the manage
ment of macular diseases. There are now treatment options for
diseases previously felt to be incurable, and for recovery of central
vision for some of these patients. The macula is the central part of
the retina (the nerve tissue lining the back of the eye). The macula
provides for the fine and discriminating vision, needed for driving,
reading and facial recognition. Thus, macular diseases result in loss
of some of the most important visual tasks, ie. - the ability to read,
the ability to drive, and the ability to recognize others. Vitreoretinal
surgery is a rapidly changing subspecialty ofophthalmology, which
has recently developed new approaches to macular diseases, such as
macular holes, macular degeneration, and subretinal
neovascularization. Research in Hawaii has contributed to these
advances.
Macular Holes
Age-related macular holes are holes in the central part of the
retina, resulting in a missing spot in the center of vision and in
distortion of vision (metamorphopsia) (Fig. 1). Macular holes are
more common in females and increase in frequency with age,
especially after age 55. Prevalence has been estimated to be 3.3 per
1000 in people over 55. This disease was previously felt to be
untreatable until 1991, when the first pilot series of vitreous surgery
showed closure of the macular hole, sealing of the retinal separation
and improvement of central vision (Fig. 2)) Marked improvements
in surgical techniques have resulted in a significant increase in
success rate from 58% in the initial reported series to over 90% in
recent series, including series reported from the Retina Center at
Pali Momi. To take a disease previously untreatable six years ago to
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a point of highly successful surgical management is truly a remark
able story in the field of vitreoretinal surgery.
The Retina Center atPali Momi, (a division of Kapiolani Medical
Center at Pali Momi), is one of 15 study centers around the nation
participating in the randomized national multi-centered trials on
macular hole surgery (The Vitrectomy for Prevention of Macular
Hole Study2’3and The Vitrectomy for Macular Hole Study).46These
studies have resulted in significant contributions to the literature
and represent the only well-controlled randomized studies on macu
lar hole surgery. The Retina Center at Pali Momi is studying the use
of serum growth factors to stimulate higher macular hole closure
rate and vitrectomy with an intraocular gas bubble to prevent
macular hole development in early stages of this disease.3 In
previously published studies ultrasonographic techniques were
utilized to demonstrate tangential traction within the vitreous gel
causing macular holes7, and macular hole surgery was shown to
allow patients even with chronic macular holes of many years in
duration to recover useful central vision following surgery.8
Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is a degenerative dis
ease of the central retina, which results in a gradual scarring of
support tissues. AMD is the most common causes of reportable
blindness in the United States, as well as here in Hawaii. It is most
common in Caucasians, especially fair and blue-eyed individuals,
and less common, although not infrequently seen in Asians. Pres
ently, preventative treatment is not proven, but studies on mineral,
antioxidant, and vitamins supplements are ongoing. Laser treatment
in the early stages of the disease is being studied in randomized
trials.
AMD has two categories
- the dry form and the wet form. The
mainstay of treatment is laser surgery for the wet form which is the
most common cause of severe vision loss. In the dry form there is
gradual scarring with slow and gradual vision loss. In the wet form,
choroidal neovascular membranes (CNVM) rapidly proliferate
causing bleeding, scarring and leaking and rapid vision loss (Fig. 3).
Laser treatment to obliterate the CNVM has been shown in large
national multi-centered trials to decrease the risk of further vision
loss.b0h1 A fluorescein angiogram (office procedure) is used to
visualize the extent of CNVM (Fig. 3). Fluorescein dye is injected
into an arm vein and an ophthalmic fundus camera with specific
filters for the fluorescent light visualizes the dye in the retinal
vessels.
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Fig 1.—Photograph of macular hole in left eye. Note visible hole approximately 800
urn in size in center of macula. Visual acuity is 20/200.
Fig. 3.—Fluorescein angiogram of retinal pigment epithelial detachment (RPED) or
blister-like formation in pigment epithelium due to subretinal neovascularization
and AMD. Note bright spot at superonasal edge of blister consistent with SRNVM,
but partially obscured by fluorescence within the RPED.
Fig. 5.—Photograph of SRNVM in patient with idiopathic inflammatory disease of
retina, called punctate inner choroidopathy. Note the grey subretinal lesion
extending into central fovea, as well as serous retinal detachment. Visual acuity
is 20/200.
Fig. 2.—Postoperative photograph following macular hole surgery. Note that
macular hole has sealed. Visual acuity is 20/40.
Fig. 4.—ICG angiogram demonstrating bright, focal area of hyperfluorescence
consistent with SRNVM in same eye as in Figure 3. Note absence of fluorescence
obscuring SRNVM within the RPED.
Fig. 6.—Postoperative photograph following subretinal surgery to remove SRNVM
showing focal hypopigmented scar in temporal macula. Note absence of grey
membrane and serous retinal detachment. Visual acuity has improved to 20/30.
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The images are captured on film or on digital camera with
computer interface, and laser treatment can be guided to the area of
CNVM. Unfortunately, the percentage ofpatients with the wet form
treatable with fluorescein angiographic criteria is less than 15%. A
new imaging technology utilizing indocyanine green (ICG) may
allow more precise localization of CNVM in select cases (Fig. 4).
This imaging technology uses digital imaging, because of the higher
sensitivity of digital cameras or video cameras to the fluorescence
of the ICG dye in the infrared range. This imaging technique has
become available in Hawaii for just over a year. With further
experience and research with this modality, more patients may
become eligible for laser surgery, although we have often found the
two imaging modalities are complimentary. For patients not treat
able with laser surgery, the prognosis for central vision is poor,
although the majority ofpatients will have normal peripheral vision.
Ongoing studies are evaluating medical treatments of CNVM by
anti-angiogenic modalities, such as oral thalidomide, vascular en
dothelial growth factor antibodies, and radiation therapy.
Choroidal neovascular membrances (CNVM) are abnormal blood
vessels growing into the subretinal space through retinal pigment
epithelium. The most common disease is AMD, but there are other
entities, which cause retinal scars and CNVM ingrowth. These
include ocular histoplasmosis syndrome (a scarring disease associ
ated with the fungus, Histoplasma capsulatum, common in the
midwest), high myopia, angioid streaks (associated most com
monly with pseudoxanthoma elasticum), trauma with choroidal
ruptures, and multiple viral or idiopathic inflammatory diseases of
the retina. Because CNVM is subretinal under
the nerve tissue thus limiting surgical access,
surgical removal was not considered until the
first successful surgical series of CNVM re
moval through a small retinotomy in 1991.12
Subretinal surgery has since develeped remark
ably with improved techniques and instrumen
tation. Most promising visual results have been
in patients with ocular histoplasmosis or idio
pathic causes (Figs 5-6).’ The initial results of
surgical removal of CNVM in AMD were
dissappointing, but research is ongoing, includ
ing exciting possible new treatment avenues of
neuroretinal and retinal pigment epithelial cell
transplantation. Subretinal surgery to remove
hemorrhage using tissue plasminogen activator
has successfully restored vision in subretinal
hemorrhage due to retinal macroaneurysms and
AMD.
Macular diseases cause loss of some of the
most important visual abilities. Recent diagnos
tic, therapeutic and surgical advances have re
sulted in recovery of central vision for many
patients with these diseases. Ongoing research
has led to advances in this rapidly changing
field, much occurring within this decade.
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The Mama Lau Cancer Care Center
(‘beniig in October 1997)
Providing leadership in cancer care services
and technologies for the people of Hawaii.
Coming in early 1998...
Gamma Knife technology...
Gamma Knife is a tremendous
alternative to brain surgery. The
first in Hawaii, this service will
provide non-invasive, relatively
,ainless, radiosurgical treatment
of brain tumors and lesions.
poem of Gamma Knife eqoipment
0 Gamma Knife BenefitsSuperior outcomesReduced health risks
St. Francis Medical Center
A sobssdiary SI. I rancis Oral/I/cane Sys/ens o/J-!siiss, No general anesthesia
2230 Liliha Street
Honolulu • Hawaii
(808) 547-6011
No incision
• Overnight hospitalization
Significantly reduced costs
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